Recombinant RSV antigens

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8563002
APP PUB NO 20100291147A1
SERIAL NO

12810196

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
GLAXOSMITHKLINE BIOLOGICALS SARUE DE L'INSTITUT 89 RIXENSART 1330

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baudoux, Guy Jean Marie Fernand Pierre Rixensart, BE 6 89
Blais, Normand Lava, CA 33 205
Rheault, Patrick Laval, CA 16 145
Ruelle, Jean-Louis Rixensart, BE 39 151

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 22, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00